BioSpace News Archive

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose websit

Medakit Ltd, a leading biotech company specialized in the production of antibody diagnosis tests for COVID-19, received on June 10th a warning letter from the Food and Drug Administration outlining their concern regarding the terminology utilized in Medakit website allegedly suggesting the use of Medakit test for " home-use” settings.

- UltraCAR-T cells eliminated tumor burden in mice following tumor rechallenge three months after prior treatment demonstrating superior expansion, persistence and improved efficacy in ovarian cancer model - - UltraCAR-T cells were selectively and effectively eliminated by kill switch activator - [22-June-2020] GERMANTOWN, Md. , June 22, 2020 /PRNewswire/ --

June 22, 2020 12:39 UTC Paragonix expands Boards to support rapid commercial growth in the heart transplant market CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Paragonix Technologies, Inc . a commercial stage company and leader in organ preservation and transport technology, today announced that Alexander K. Arrow, MD, CFA has joined its Board of Directors. Dr. Arrow is a medical technology executive with 24 years of experience in management and finance roles at small and me

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that the Company launched a new immunology test product line in China during the week of June 15, 2020. This immunology test product line consists of multiple government-approved immunology related tests, and relies on

Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapy Inhibigens alter the tumor microenvironment and drive tumor hyperprogression Inhibigens abolish both global and tumor antigen-specific T cell activity CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new and important insi

Acepodia, a biotechnology company developing cancer immunotherapies based on its novel ACC (Antibody Cell Conjugation) technology platform, today announced that it presented preclinical data on ACE1702, a natural killer cell (NK cell) therapy being developed as a treatment for HER2-expressing solid tumors. The data was presented in a digital

Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, presents insights from preclinical studies on its PD1-41BB switch receptor at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place from 22 – 24 June 2020. The e-poster is available online today on the first day of the virtual conference as well as

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer (CRC).

- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo proteins using split molecule technology may increase therapeutic index - - Company to host Investor R&D Showcase Tuesday, June 23 at 3:30 p.m. PT / 6:30 p.m. ET - SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical com